BD
(NYSE: BDX)
today voluntarily posted a product security bulletin for a number of vulnerabilities with its Alaris infusion system.
Franklin Lakes, New Jersey-based BD recently identified eight vulnerabilities. These vulnerabilities are associated with the BD Alaris system with Guardrails Suite MX, versions 12.1.3 and earlier.
The company discovered the vulnerabilities through routine internal security testing as part of its software development life cycle. This includes vulnerability scanning, code analysis, threat modeling and penetration testing.
Get the full story at our sister site, Drug Delivery Business News.